van de Ven Rieneke
Otolaryngology/Head and Neck Surgery, Amsterdam UMC-Locatie VUMC, Amsterdam, The Netherlands
Cancer Biology and Immunology, Cancer Centre Amsterdam, Amsterdam, The Netherlands.
J Immunother Cancer. 2025 Jul 11;13(7):e012125. doi: 10.1136/jitc-2025-012125.
T-cell immunoglobin and mucin-domain containing molecule 3 (TIM-3) is an immune checkpoint receptor and a target for immune checkpoint blockers (ICBs). Unfortunately in human patients the success rate of anti-TIM-3 ICB remains rather limited. Multiple immune cells express TIM-3 and their functioning is affected by receptor-ligand interactions. Four ligands of TIM-3 have been identified: high-mobility group protein B1, galectin-9, phosphatidylserine and carcinoembryonic antigen cell adhesions molecule 1. Wang investigated which of these ligands interact with TIM-3 on natural killer (NK) cells, impairing NK cytotoxicity and proliferation. They demonstrated that galectin-9 was able to inhibit NK cell cytotoxicity in a TIM-3-dependent manner, and to block NK cell proliferation through interaction with CD44 on NK cells. They also showed that in head and neck squamous cell carcinoma (HNSCC), a high TIM-3+NK cell transcriptional signature was linked to poor survival probability, specifically in HNSCC caused by human papillomavirus infection. This study enhances our understanding of why anti-TIM-3 ICB may not be so effective as monotherapy and provides leads toward rational design of combination strategies and patient selection.
含T细胞免疫球蛋白和粘蛋白结构域分子3(TIM-3)是一种免疫检查点受体,也是免疫检查点阻断剂(ICB)的作用靶点。遗憾的是,在人类患者中,抗TIM-3 ICB的成功率仍然相当有限。多种免疫细胞表达TIM-3,其功能受受体-配体相互作用的影响。已鉴定出TIM-3的四种配体:高迁移率族蛋白B1、半乳糖凝集素-9、磷脂酰丝氨酸和癌胚抗原细胞粘附分子1。Wang等人研究了这些配体中哪些与自然杀伤(NK)细胞上的TIM-3相互作用,从而损害NK细胞的细胞毒性和增殖。他们证明,半乳糖凝集素-9能够以TIM-3依赖的方式抑制NK细胞的细胞毒性,并通过与NK细胞上的CD44相互作用来阻断NK细胞的增殖。他们还表明,在头颈部鳞状细胞癌(HNSCC)中,高TIM-3+NK细胞转录特征与低生存率相关,特别是在由人乳头瘤病毒感染引起的HNSCC中。这项研究增进了我们对抗TIM-3 ICB作为单一疗法可能效果不佳原因的理解,并为联合策略的合理设计和患者选择提供了线索。